BioPartnering Europe 2005 Exhibitor Profiles.

LONDON -- BioPartnering Europe 2005 takes place 09 - 11 October at Queen Elizabeth II Conference Centre in London, United Kingdom. For in-depth information about the event visit http://www.techvision.com/bpe/#.

Below are profiles from BioPartnering Europe 2005 exhibitors; breaking news releases are available at http://www.tradeshownews.com, Business Wire's trade show, conference, and event news resource.

Business Wire is the official news wire service for BioPartnering Europe 2005.

Company:  Ambit Biosciences Corporation
Booth/Stand:  Group 4, Booth 20
Media Contact:  Rachel Lipsitz
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.ambitbio.com

    With unprecedented speed and efficiency, Ambit's proprietary
kinase platform, KinomeScan, identifies and quantifies binding
interactions between small molecules and human proteins. KinomeScan
has been validated through partnerships with Bristol-Myers Squibb
Company, GlaxoSmithKline, Pfizer and Roche as well as articles in PNAS
and Nature Biotechnology. Ambit utilized KinomeScan to develop kinase
inhibitors for the treatment of cancer and plans to initiate clinical
trials in 2006. Ambit has raised a total of $51 million from investors
including Perseus-Soros Biopharmaceutical Fund, Forward Ventures,
Roche, Avalon Ventures, MDS Capital, Genechem and GIMV NV.

Company:  Arrow Therapeutics Ltd
Booth/Stand:  Open House Presenter: Group 4, Booth 14
                                    (Tues 11th Oct, 1:30-4pm)
Media Contact:  Ken Powell
Investor Relations Contact:  Annie Clayton
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.arrowt.co.uk

    Founded in 1998, Arrow Therapeutics is a privately owned
pharmaceutical company based in central London. Our research is
focused exclusively on the discovery and development of anti-infective
therapeutics. We specialise in small molecule drugs with novel
mechanisms of action that will address the urgent unmet medical needs
in the antiviral and antibacterial fields. Our in-house research
efforts have resulted in compounds against Respiratory Syncytial Virus
and Hepatitis C in addition to novel antibiotics. With our research
approach well established we are now stepping up our development
activities. The leading RSV compound completed Phase I in June 2004
and Phase IIa trials began in the second half of 2004. Our lead
Hepatitis C compound is planned to enter clinical trials during 2006.
Novel antibiotic compounds are currently at lead optimisation stage.

Company:  Curalogic A/S
Booth/Stand:  Emerging Company Presentation, Monday 3:45 pm
Media Contact:  Peter Moldt, CEO
Phone:  [phone]
E-mail:  pmo@curalogic A/S
Web:  www.curalogic.com

    Curalogic is developing novel oral immunotherapy products by
applying its proprietary oral drug delivery technologies for the
treatment of allergies and diseases. The allergy market was in 2004
greater than USD 10 Billion. Curalogic has three open US INDs. The
lead program is development of an oral vaccine for the treatment of
ragweed allergy which is entering phase III. Allergy immunotherapy has
been documented to give a 30-40% reduction in allergy symptoms over
self-administered antihistamine. In comparison, antihistamines provide
only a modest approximately 15% reduction in allergy symptoms over
placebo. Furthermore, immunotherapy in general has been shown to be
curative.

Company:  CyGenics
Booth/Stand:  23
Ticker Symbol & Exchange:  CYN ASX
Media Contact:  Ronald Hee
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.cygenics.com

    CyGenics is a cell therapy company focused on the development and
commercialisation of adult stem cell-related products, services,
applications and technologies. From its headquarters in Australia,
CyGenics operates four subsidiaries: Singapore-based CordLife
(tissue banking services, in particular, cord blood banking) and Cell
Sciences (consumable cell culture products), and Cytomatrix (cell
therapeutics and technology development) based in Boston, USA, and
CytoVations (new product development) based in New Jersey, USA.
CyGenics is listed on the Australian Stock Exchange, under the symbol
CYN. For more information, please visit www.cygenics.com.

Company:  Emergent BioSolutions Limited
Booth/Stand:  Booth 7 (Group 3)
Media Contact:  Kim Root
Investor Relations Contact:  Jonathan Pockson
Phone:  [phone]
E-mail:  [e-mail]
Web:  http://www.ebse.com

    Emergent BioSolutions' business is focused on two main areas:
biodefence and commercial products. The company has assembled a
highly capable team with broad experience of pharmaceutical
development gained within different product and commercial
environments. EBS will actively manage its portfolio of clinical
assets to exploit the opportunities afforded by project BioShield,
commercial vaccines and immunotherapeutics. The company will invest
internally in those programs where it can lever its skills and
expertise to best effect and retain value for the company. At the
appropriate stage, it will also seek partnerships with organizations
that are able to bring unique assets and capabilities to the
collaboration, which will maximize the probability of early commercial
launch and success.

Company:  Enigma Diagnostics Ltd
Booth/Stand:  720
Media Contact:  Dr Ian George
Investor Relations Contact:  Dr John Thornback
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.enigmadiagnostics.com

    Enigma Diagnostics is on a mission to take molecular testing out
of the laboratory. Enigma's portable automatic platform has the
accuracy and sensitivity of laboratory based instruments and,
combining all procedures in an integrated package, provides a result
from raw sample in about 20 minutes. This platform has many potential
markets and Enigma is developing a focused portfolio of products for
high growth market opportunities in veterinary testing and point of
care clinical diagnostics.

Company:  ERGOMED GROUP
Booth/Stand:  24; Monday 2:30-5:00
Media Contact:  Klemens Schuette
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.ergomed-cro.com

    Ergomed presents its new flexible co-development model for biotech
companies. The comprehensive model addresses the needs for early stage
clinical trials, clinical services and finance. Ergomed, the
transatlantic drug development company, offers the full-range of
clinical facilities and regulatory experience to efficiently drive
compounds through the clinical and approval processes in Europe and
the US. Ergomed provides the full range of drug development services,
including: trial design and strategy, site management, project
management, monitoring, pharmacovigilance, quality assurance, data
management and regulatory strategies. The Phase I Unit provides access
to special patient populations, including: oncology; neurology;
hepatic; and renal impaired patients.

Company:  Evolva
Media Contact:  [e-mail]
Investor Relations Contact:  [e-mail]
Phone:  [phone]
Web:  www.evolva.com

    Evolva is a drug discovery company bringing a new paradigm in that
field. Our technology, Watchmaker(R), combines the exploration of
uncharted chemical space with a unique evolution-based process leading
to the discovery and optimization of small chemical molecules for
therapeutic targets. For diabetes, we have rapidly evolved a new class
of partial PPAR gamma agonists with a specific co-activator
recruitment profile, for one, they do not induce adipocyte
differentiation. We are also active in oncology where we evolve small
molecules to disrupt Protein:Protein interaction. We are presenting at
BPE: Monday, October 10, 12:15-12:29 -- Whittle Room, 3rd floor QEII
Conference Centre.
www.evolva.com

Company:  Evotec
Booth/Stand:  8G56

Ticker Symbol & Exchange:  EVT, Frankfurt Stock Exchange,
                           Prime Standard
Media Contact:  Anne Hennecke
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.evotec.com

    Your fully integrated drug discovery and development service
provider of choice. Through an unmatched range of integrated
scientific capabilities, innovative technology platforms and disease
orientated research expertise, Evotec has grown to become a market
leading solution provider to pharmaceutical and biotechnology
companies globally. We discover and develop novel pharmaceuticals
through both service partnerships and investment into a CNS discovery
programme. Our skills and expertise in biology, screening and
chemistry enable us to generate value by accelerating the discovery
and development process, managing risk efficiently, thereby reducing
the time and cost of bringing new drugs to the market for our
partners.

Company:  ImaRx Therapeutics, Inc.
Booth/Stand:  Group 4 Booth 14
Media Contact:  Brad Zakes, VP, Business Development
Investor Relations Contact:  Greg Cobb, CFO
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.imarx.com

    ImaRx Therapeutics develops targeted, NanoInvasive(TM) solutions
for cardiovascular disease. As innovators in the field, ImaRx has
developed late-stage NanoInvasive therapies that provide localized,
highly targeted treatments that are significantly less invasive than
currently available alternatives. ImaRx's lead product candidate is a
Phase II therapeutic for stroke that extends the treatment window,
thereby increasing the overall patient population able to be treated.
ImaRx has already achieved commercial success with the development of
the world's best selling nanobubble. The company is strategically
poised for growth through the acquisition of two phase III
thrombolytic compounds and the initiation of the first ever
NanoInvasive trials, which already show promising clinical results in
cardiovascular disease.

Company:  Immatics biotechnologies GmbH
Media Contact:  Niels Emmerich
Investor Relations Contact:  Joerg Scheidle
Phone:  [phone]
E-mail:  [e-mail], [e-mail]
Web:  www.immatics.com

    immatics is a biopharmaceutical company dedicated to the
development of innovative cancer immunotherapeutics. immatics'
proprietary basis of tumor-associated peptides (TUMAPs) provides a
huge opportunity for development of novel anti cancer vaccines.
Having shown promising clinical results for first TUMAPs in pilot
trials, immatics now enters into clinical development in renal cell
carcinoma (RCC) with its first multi-TUMAP product candidate IMA901.
With XPRESIDENT(TM), immatics owns a unique technology allowing the
identification of thousands of TUMAPs directly from primary tumor
tissue. immatics was founded in 2000 as a spin-off from the Institute
of Immunology at the University of Tuebingen (Hans-Georg Rammensee).

Company:  Inpharmatica
Booth/Stand:  Group 3 Tuesday October 11th; 9:45 -- 12:15
Media Contact:  Tatiana Yablonsky
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.inpharmatica.com

    Inpharmatica Ltd is a selective drug discovery company applying
its expertise in structural dynamics, computational biology, and
medicinal chemistry to the identification of quality drug targets,
chemical leads, and drug candidates. Our technology thereby reduces
attrition in the drug discovery process. These technologies are
applied to our own successful discovery program and also made
available to partners through an integrated chemogenomics suite.
Linking genomic and proteomic space with chemistry thus provides a
unique approach to hit identification, lead generation, and drug
optimisation for druggable targets.

Company: InSymbiosis
Media Contact:  Mr Marcel Pinchevsky, Chief Operating Officer
Investor Relations Contact:  Dr Dean Wenham, President and CEO
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.insymbiosis.com

    InSymbiosis provides research services to the global
biopharmaceutical industry. InSymbiosis' expertise covers early stage
research, drug discovery, lead optimization, pharmaceutical
development and clinical development. The InSymbiosis model presents a
unique enabling approach to our clients via our value drivers:

    --  Accountability: InSymbiosis plan, design and execute parts or
        all of your projects.

    --  Flexibility: Utilize our pool of R&D resources only when you
        need them, keeping costs low.

    --  Cost effectiveness: InSymbiosis allow our international
        clients to benefit from our cost efficient Canadian location.

    --  Productivity: By combining the above, costs are reduced and
        schedules compressed resulting in maximal productivity.

Company:  MaxCyte Inc.
Media Contact:  Douglas Doerfler, President and CEO
Investor Relations Contact:  Ronald Holtz, Chief Financial Officer
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.maxcyte.com

    MaxCyte is a cell therapeutics company with a pipeline of several
drug candidates. Programs in development are based on MaxCyte's
platform technology which breaks down the barriers to ex vivo cell
loading. MaxCyte's pipeline includes one product in Phase I/II
clinical trials for the treatment of Chronic Lymphocytic Leukemia
(CLL) and several preclinical candidates to treat various diseases
with unmet needs. The company also offers its unparalleled,
customizable flow based cell loading technology to partners who are
developing cell therapies and gene therapies. Partners are currently
developing therapeutics for pulmonary and cardiovascular diseases,
infectious diseases, cancer, and in regenerative medicine.

Company:  MedPharm Ltd
Booth/Stand:  Open-House Presentation Nb 15
              Monday, October 10  2:30-5:00
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.medpharm.co.uk

    MedPharm is a drug delivery and contract service company committed
to the creation and development of novel systems, particularly for
topical (skin, nail, mucous membranes) and airway drug formulations.
Projects range from simple feasibility tests, dosage design and
optimization through to preparation of GMP clinical supplies for Phase
I/II trials with guaranteed smooth technology transfer to
manufacturing sites. MedPharm has been directly involved in the
development of four products currently on the market in the EU and/or
US. In parallel to its services, MedPharm invests in its own IP in
novel drug delivery technologies which can be licensed to clients.

Company:  MERISTEM Therapeutics
Booth/Stand:  OPEN-HOUSE presentation Tuesday October 11th
              group 3 no. 24
              9:45AM-12:15AM And Booth in CORDIA exhibition 940
Phone:  [phone]
E-mail:  [e-mail]
Web:  meristem-therapeutics.com

    MERISTEM(R) Therapeutics is a European biotechnology company and
leader in recombinant protein production in corn and tobacco. The
know-how of the company extends from the cloning of genes coding the
protein of interest to the purification of active substance at
pharmaceutical grade. Our lead product is MERISPASE(R), a gastric
lipase used in the treatment of Exocrine Pancreatic Insufficiency, in
particular for Cystic Fibrosis and Chronic Pancreatitis patients. This
product is ready for co-development. Our platform allows for the
production of a wide range of complex proteins (e.g. antibodies for
cancer treatments, collagen, human allergens, lactoferrin). Our
partners can benefit from our platform with increased production
flexibility, lower production costs, and low capital investment.

Company:  OctoPlus
Booth/Stand:  Booth 13, Tuesday 13.30 -- 16.00 hrs
Media Contact:  Joost Holthuis, CEO
Investor Relations Contact:  Hans Pauli, CFO
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.octoplus.nl

    OctoPlus is a clinical-stage, product-oriented drug delivery
company focused on parenteral controlled release. Products in
development include amongst others controlled release formulations of
recombinant human alfa interferon and growth hormone. OctoPlus is also
an internationally established provider of pharmaceutical development
services and cGMP manufacturing to biotech and pharma companies
worldwide. Recent news: on September 26th, OctoPlus and SingVax
announced their collaboration to develop a single-shot Japanese
encephalitis (JE) vaccine. Existing JE vaccines typically require two
or three doses. By creating a single-shot JE vaccine the companies aim
to achieve increased patient compliance and greater efficacy of the
vaccine.

Company:  Optimata Ltd.
Media Contact:  Mr. Guy Malchi
Phone:  [phone]
E-mail:  [e-mail]
Web:   www.optimata.com

    Active since 2000, privately owned, interdisciplinary
science-based, Optimata Ltd. develops and markets computerized
products -- Virtual Patient engines -- for accelerating drug
development and optimizing patient treatment. Using Bio-Mathematics to
develop a predictive Bio-simulation software toolkit, these products
provide a comprehensive drug development solution, from the
pre-clinical phase through treatment personalization. They thoroughly
unfold drug/patient dynamic interactions, enabling drug developers to
perform rapid virtual clinical trials and to forecast optimal drug
treatment. This allows:

    --  Comprehensive toxicity and efficacy profile prediction

    --  Optimizing fit between drug protocols and sub populations

    --  Drug indication selection / expansion

    --  Drug salvage and drug repurposing

Company:  PAION
Booth/Stand:  Group 2, Booth 21
Ticker Symbol & Exchange:  PA8
Media Contact:  Dr. Peer Nils Schroder
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.paion.de

    PAION, a biopharmaceutical company based in Aachen, Germany, aims
to become a leader in developing and commercialising innovative drugs
for the treatment of stroke and other thrombotic diseases for which
there is a substantial unmet medical need. PAION intends to build an
integrated drug portfolio by exploiting its expertise in identifying
compounds, licensing or otherwise acquiring them and advancing them
through the clinical development and regulatory approval process.
PAION's lead product Desmoteplase for the treatment of acute ischaemic
stroke is currently in Phase III. During the first half-year 2005,
PAION employed on average 59 people.

Company:  Pharmagene Laboratories Ltd
Booth/Stand:  21
Ticker Symbol & Exchange:  PGN
Media Contact:  Ronald Openshaw
Investor Relations Contact:  Financial Dynamics
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.pharmagene.com

    Pharmagene provides human tissue-based drug discovery services
using fully consented human tissue for which it has established, and
maintains, one of the most effective tissue supply networks in the
world. Pharmagene provides services in human functional pharmacology,
biochemical and safety pharmacology and gene/protein profiling in many
therapeutic areas. These techniques are used in target validation to
evaluate which targets are relevant to human disease, in compound
validation to aid prioritisation of pre-clinical candidate compounds
prior to entry into the clinic. They can also be used to extract
greater value from existing compounds, by identifying possible new
indications. Pharmagene announced on 19th Sept 2005, it's intention to
merge with Asterand, a Detroit based Biotech company that specialises
in the supply of high quality human tissue and tissue-based services.
For more information go to our website www.pharmagene.com.

Company:  PharmaLinks
Booth/Stand:  Group 4 booth 22
Media Contact:  Anne Muir
Phone:  [phone]
E-mail:  [e-mail]
Web:  http://www.pharmalinks.org

    PharmaLinks -- helping pharmaceutical and biotechnology companies
go from concept to compound by providing flexible solutions to advance
drug discovery and development projects. PharmaLinks is based on the
expertise and facilities of two Scottish universities -- the
University of Glasgow and University of Strathclyde. PharmaLinks draws
on 1200 biomedical researchers providing access to expertise in most
diseases and therapeutic areas (cancer, cardiovascular, neuroscience,
inflammation, infection) and key technology areas (synthetic/medicinal
chemistry, functional pharmacology, models, formulation/drug delivery
and clinical trials), as well as proprietary lead compounds. From
early-stage compounds to bespoke discovery programmes, we offer
research solutions to advance drug discovery and development.

Company:  Proteome Sciences plc
Booth/Stand:  Open House Presentation -- Group 4
              (Tues Oct 11th, 1.30-4) -- Booth 10
Ticker Symbol & Exchange:  PRM/LSE
Media Contact:  James Green -- Commercial Director
Investor Relations Contact:  Christopher Pearce -- Chief Executive
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.proteomics.com

    Proteome Sciences, a global leader in applied proteomics, uses
high sensitivity proprietary technologies to detect differentially
expressed proteins in diseases. The protein biomarkers discovered in
body fluids or tissues are validated, developed and commercialised as
diagnostic, prognostic or therapeutic products through strategic
alliances and out-licensing. Through its unique ProteoSHOP(R) toolkit,
Proteome Sciences provides high sensitivity/high throughput proteomics
solutions, including traditional two dimensional gel-based
electrophoresis (2DE) and proprietary gel-free protein sequence tag
technologies (PST(R), qPST(TM)& TMT(R)), to major pharma,
biotechnology and diagnostic companies, to discover and exploit
protein biomarkers. Sensitizer(R) chemical mass tags have been
developed separately as a series of stand-alone reagents.

Company:  RNTECH SAS
Booth/Stand:  4 -- Tuesday October 11, 10:00 to 12:30
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.rntech.com

    "RNTech" is a leading company in early stage digestive tract
cancer diagnostic tools and drugable targets discovery and development
supported by an exclusive access to proprietary high standard
biological material and clinical data bank combined with original
discovery processes backed by state of the art technology platforms.
From the origin highest ethical and technical standards are applied.
The exclusive collaboration with the "Fundeni Institute" in Bucharest
has built an original biological and clinical data bank representing
currently 15,000+ samples of biological material. "RNTech" is
associated with DNAVision (www.dnavision.be) to perform collaborative
and contract research and jointly market products and services.

Company:  TopoTarget
Booth/Stand:  Monday 10th Oct 10am-12.30pm, Booth 15
Ticker Symbol & Exchange:  TOPO (CSE)
Media Contact:  Dr Peter Buhl Jensen (CEO)
Investor Relations Contact:  Hanne Leth Hillman
                             (Director, Investor Relations)
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.TopoTarget.com

    TopoTarget is a fully integrated biopharmaceutical company with
operations in Denmark, UK and Germany, dedicated to developing
improved therapies for cancer, with a strong focus on cancer patient
needs. The company combines an in-depth understanding of the molecular
mechanisms of cancer and use of predictive clinical models, with a
wide experience in clinical oncology practice. TopoTarget's pipeline
is balanced between niche cancer products which it aims to market
itself in Europe, and novel compounds of broad potential application
which will be marketed by partners. The pipeline includes eight
programmes in clinical trials, the most advanced of which was
submitted to EMEA for marketing approval in August 2005.

Company:  Tranzyme Pharma
Booth/Stand:  5
Media Contact:  Vincent Parrino ([e-mail])
Investor Relations Contact:  Richard Eisenstadt
                             ([e-mail])
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.tranzyme.com

    Tranzyme Pharma is a leading biopharmaceutical company developing
novel orally bioavailable, small molecule therapeutics for the
treatment of gastrointestinal (GI) diseases. The Company's candidate
drugs originate from its own discovery pipeline of proprietary
compounds with high affinity for validated and druggable targets in
the GI tract. Tranzyme is developing mechanism-based therapeutics for
post-operative ileus, diabetic gastroparesis, irritable bowel syndrome
(diarrhea-type) and functional dyspepsia and is on track to enter the
clinic with its first product in the first quarter of 2006. Tranzyme
is leveraging its technologies through internal programs and
partnerships to drive the discovery and development of new
therapeutics.

Company:  Trigen Holdings AG
Booth/Stand:  19 -- Open House presenter Tuesday afternoon
Media Contact:  Ashley Tapp, Head of Corporate Communications
Phone:  [phone]
E-mail:  44 20 7004 2631
Web:  www.trigen.co.uk

    Trigen Holdings AG is a biopharmaceutical company with operations
in London and Munich and a leader in cardiovascular drug discovery and
development, focusing on thrombosis and vascular dysfunction. The
company's product pipeline includes TGN 255, TGN 167 and PR-15 (which
is expected to enter the clinic later this year). The company also has
an extensive portfolio of exciting pre-clinical and discovery stage
programmes targeting thrombosis, atherosclerosis and other
cardiovascular pathologies. The company benefits from in-house
discovery and development expertise in small molecule and protein
therapeutics, bringing together existing highly-skilled chemistry and
biology teams in the UK and Germany. Trigen also benefits from two
established discovery platforms, SIGSCREEN(R) and THROMSCAN(R) which
have been applied in collaborations with a number of multinational
pharmaceutical companies.

Company:  TriStar Technology Group, LLC
Booth/Stand:  16
Media Contact:  Milan Bhagat
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.tristargroup.us

    TriStar brings the power of high throughput tissue analysis to
significantly facilitate and accelerate in situ target discovery and
validation.

    We have one of the world's largest repositories of human cancer
Tissue Micro Arrays (TMAs) and work with leading research based
Pharmaceutical companies in three important phases of drug
development:

(a) Determining the prevalence of target gene alterations in one or
    several cancer types.

(b) Developing predictive methods to identify those patients with the
    highest likelihood of benefiting from a new therapy.

(c) Screening tissues from clinical study patients for subsequent
    molecular analyses to be able to retrospectively identify
    predictive molecular markers.

    Dr. Guido Sauter, Director of the Institute of Pathology at the
University of Hamburg, leads our scientific team. Dr Sauter has been
working with therapeutic target genes since 1993 when he was the first
pathologist to use HER2 FISH probes.

    Our multi tumor arrays enable the screening of 10 -- 50 samples
each from 120 human cancers for the expression of novel targets,
providing valuable IP for the development of both small molecule as
well as antibody therapeutics. TriStar cancer specific arrays have up
to 2200 donor specimens supported by raw and tumor-specific survival
information.

    We now offer formalin fixed / frozen tissue arrays, tissue
sections, RNA, DNA and Serum for research in the areas of Oncology,
CNS, Autoimmune, and Cardiovascular disease.

Company:  YM BioSciences Inc.
Booth/Stand:  Group 3, Booth 14
Ticker Symbol & Exchange:  AMEX -- YMI, TSX -- YM, AIM -- YMBA
Media Contact:  James Smith
Investor Relations Contact:  Carolyn McEwen
Phone:   [phone]
E-mail:  [e-mail]
Web:  www.ymbiosciences.com

    YM BioSciences' lead drug, tesmilifene, is a chemopotentiator that
completed enrollment in a 700-patient pivotal PIII trial in metastatic
breast cancer. Results from the first PIII trial demonstrated a
substantial increase in survival for women treated with the
combination of tesmilifene/chemotherapy compared to chemotherapy
alone. YM is also developing nimotuzumab, an anti-EGFr humanized
monoclonal antibody, and its anti-GnRH, anti-cancer vaccine, Norelin,
for which PII data was released. In 05/2005, YM acquired DELEX, a
biotechnology company developing AeroLEF, an inhaled formulation of
fentanyl, to treat acute pain, which completed a PIIa trial with
positive results and a randomized PIIb pain trial has been cleared to
start.

Company:  XOMA (US) LLC
Booth/Stand:  Group 3, Booth 5
Ticker Symbol & Exchange:  XOMA
Media Contact:  Ellen Martin, Kureczka/Martin Associates
Phone:  [phone]
E-mail:  [e-mail]
Web:  www.xoma.com

    XOMA is a leader in the discovery, development and manufacturing
of therapeutic monoclonal antibodies (mAbs). XOMA's mAb platform
includes leading commercial antibody phage display libraries,
hybridoma, Human Engineering(TM) and affinity maturation technologies,
and a fully integrated product development infrastructure, including
cell line and process development, preclinical and clinical functions,
and manufacturing. XOMA's pipeline includes both proprietary products
and collaborative programs. XOMA receives royalties for RAPTIVA(R)
marketed in the US by Genentech Inc. and ex-US by Serono SA for the
treatment of moderate-to-severe psoriasis. Other strategic
collaborators include Aphton Corporation, Chiron Corporation and
Lexicon Genetics.

Note to Editors: Business Wire's PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content to experts, company profiles, email alerts, survey services and other media services.

Note to Event Organizers: Add your trade show, conference, or event to www.tradeshownews.com, Business Wire's online event calendar. For information, email [e-mail].